Literature DB >> 29749443

TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells.

Peng Wang1, Na Shen1, Danzheng Liu1, Xianhui Ning1, Daquan Wu1, Xinsheng Huang1.   

Abstract

Nasopharyngeal carcinoma (NPC) is a common cancer occurring primarily in East Asia and Africa. The high rate of recurrence and metastasis of NPC continuously endangers the health of patients. The present study aimed to identify the underlying mechanisms involved in the progression of NPC and provide experimental basis to develop a novel and efficient agent against NPC. The present study measured the expression level of tripartite motif containing 24 (TRIM24) in tumor tissues from NPC patients using reverse transcription quantitative polymerase chain reaction. Subsequently, Cell Counting kit‑8 and flow cytometry were used to detect the cell proliferation and apoptosis of NPC cell lines HONE1 and CNE1 cells where the TRIM24 gene was knocked‑down with small interfering RNA (siRNA). Further, caspase kits and western blot analysis were used to detect the expression of apoptosis and angiogenesis‑associated proteins. The present study detected a higher expression level of TRIM24 in tumor tissues and NPC cell lines and lower cell viability and higher apoptotic rate were observed when TRIM24 was silenced. Meanwhile, upregulated caspase‑3 and caspase‑9 indicated induced cell apoptosis in HONE1 and CNE1 cells following the treatment with TRIM24 siRNA. Additionally, the downregulated expression level of vascular endothelial growth factor (VEGF) and VEGF receptor 2 suggested inhibited angiogenesis of NPC cells. Additionally, the reduced levels of janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) indicated a blocked JAK2/STAT3 signaling pathway. However, there was no direct evidence that inactivation of the JAK2/STAT3 signaling pathway was involved in regulation of siTRIM24, these results suggested that TRIM24 has an important role in the growth of NPC. Additionally, silenced TRIM24 may lead to inhibited cell proliferation and induced cell apoptosis in NPC cells. The limitation of this study was that HONE1, CNE1 and CNE2 cells may have been contaminated with other cells. Further experiments with validated NPC cells may be needed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29749443     DOI: 10.3892/mmr.2018.8946

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  miR-339-3p inhibits cell growth and epithelial-mesenchymal transition in nasopharyngeal carcinoma by modulating the KAT6A/TRIM24 axis.

Authors:  Pei Gao; Kun Zhao; Wuhao Lu; Liang Wang; Peng Zhang
Journal:  Int J Clin Oncol       Date:  2022-08-17       Impact factor: 3.850

2.  TRIM24 promotes colorectal cancer cell progression via the Wnt/β-catenin signaling pathway activation.

Authors:  Hong Tian; Hongmei Zhao; Bo Qu; Xiaoli Chu; Xing Xin; Qingwei Zhang; Weizhou Li; Shida Yang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple.

Authors:  Runa Zhang; Si-Wei Li; Lijuan Liu; Jun Yang; Guofu Huang; Yi Sang
Journal:  Oncogenesis       Date:  2020-05-07       Impact factor: 7.485

Review 4.  The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members.

Authors:  Michael A Mandell; Bhaskar Saha; Todd A Thompson
Journal:  Front Pharmacol       Date:  2020-03-11       Impact factor: 5.810

5.  Exosomal miR-106a-5p accelerates the progression of nasopharyngeal carcinoma through FBXW7-mediated TRIM24 degradation.

Authors:  Chang-Wu Li; Jing Zheng; Guo-Qing Deng; Yu-Guang Zhang; Yue Du; Hong-Yan Jiang
Journal:  Cancer Sci       Date:  2022-03-29       Impact factor: 6.518

Review 6.  TIF1 Proteins in Genome Stability and Cancer.

Authors:  Roisin M McAvera; Lisa J Crawford
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.